EADSG Guidelines: Insulin Therapy in Diabetes

Abstract

A diagnosis of diabetes or hyperglycemia should be confirmed prior to ordering, dispensing, or administering insulin (A). Insulin is the primary treatment in all patients with type 1 diabetes mellitus (T1DM) (A). Typically, patients with T1DM will require initiation with multiple daily injections at the time of diagnosis. This is usually short-acting insulin or rapid-acting insulin analogue given 0 to 15 min before meals together with one or more daily separate injections of intermediate or long-acting insulin. Two or three premixed insulin injections per day may be used (A). The target glycated hemoglobin A1c (HbA1c) for all children with T1DM, including preschool children, is recommended to be < 7.5% (< 58 mmol/mol). The target is chosen aiming at minimizing hyperglycemia, severe hypoglycemia, hypoglycemic unawareness, and reducing the likelihood of development of long-term complications (B). For patients prone to glycemic variability, glycemic control is best evaluated by a combination of results with self-monitoring of blood glucose (SMBG) (B). Indications for exogenous insulin therapy in patients with type 2 diabetes mellitus (T2DM) include acute illness or surgery, pregnancy, glucose toxicity, contraindications to or failure to achieve goals with oral antidiabetic medications, and a need for flexible therapy (B). In T2DM patients, with regards to achieving glycemic goals, insulin is considered alone or in combination with oral agents when HbA1c is ≥ 7.5% (≥ 58 mmol/mol); and is essential for treatment in those with HbA1c ≥ 10% (≥ 86 mmol/mol), when diet, physical activity, and other antihyperglycemic agents have been optimally used (B). The preferred method of insulin initiation in T2DM is to begin by adding a long-acting (basal) insulin or once-daily premixed/co-formulation insulin or twice-daily premixed insulin, alone or in combination with glucagon-like peptide-1 receptor agonist (GLP-1 RA) or in combination with other oral antidiabetic drugs (OADs) (B). If the desired glucose targets are not met, rapid-acting or short-acting (bolus or prandial) insulin can be added at mealtime to control the expected postprandial raise in glucose. An insulin regimen should be adopted and individualized but should, to the extent possible, closely resemble a natural physiologic state and avoid, to the extent possible, wide fluctuating glucose levels (C). Blood glucose monitoring is an integral part of effective insulin therapy and should not be omitted in the patient's care plan. Fasting plasma glucose (FPG) values should be used to titrate basal insulin, whereas both FPG and postprandial glucose (PPG) values should be used to titrate mealtime insulin (B). Metformin combined with insulin is associated with decreased weight gain, lower insulin dose, and less hypoglycemia when compared with insulin alone (C). Oral medications should not be abruptly discontinued when starting insulin therapy because of the risk of rebound hyperglycemia (D). Analogue insulin is as effective as human insulin but is associated with less postprandial hyperglycemia and delayed hypoglycemia (B). The shortest needles (currently the 4-mm pen and 6-mm syringe needles) are safe, effective, and less painful and should be the first-line choice in all patient categories; intramuscular (IM) injections should be avoided, especially with long-acting insulins, because severe hypoglycemia may result; lipohypertrophy is a frequent complication of therapy that distorts insulin absorption, and therefore, injections and infusions should not be given into these lesions and correct site rotation will help prevent them (A). Many patients in East Africa reuse syringes for various reasons, including financial. This is not recommended by the manufacturer and there is an association between needle reuse and lipohypertrophy. However, patients who reuse needles should not be subjected to alarming claims of excessive morbidity from this practice (A). Health care authorities and planners should be alerted to the risks associated with syringe or pen needles 6 mm or longer in children (A).

References 167

1. 1.

   International Diabetes Federation. Diabetes atlas—8th edition. http://www.diabetesatlas.org/resources/2017-atlas.html. Accessed Dec 19, 2017.

   Not in our library

2. 2.

   Institute for Health Metrics and Evaluation Human Development Network. The World Bank. The global burden of disease: generating evidence, guiding policy—Sub-Saharan Africa Regional Edition. Seattle: IHME; 2013.

   Not in our library

3. 3.

   UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854-865.

   Not in our library10.1016/s0140-6736(98)07037-8

4. 4.

   UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853.

   Not in our library10.1016/s0140-6736(98)07019-6

5. 5.

   The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986.

   Not in our library10.1056/nejm199309303291401

6. 6.

   Bolen S, Tseng E, Hutfless S, et al. Diabetes medications for adults with type 2 diabetes: an update. Comparative effectiveness review no. 173. (Prepared by the Johns Hopkins University Evidence-based Practice Center under Contract No. 290-2012-00007-I.). AHRQ Publication No.16-EHC013-EF. Rockville: Agency for Healthcare Research and Quality; 2016. http://www.effectivehealthcare.ahrq.gov/reports/final.cfm.

   Not in our library

7. 7.

   Wirtz VJ, Knox R, Cao C, Mehrtash H, Posner NW. Insulin market profile. 2016.

   Not in our library

8. 8.

   Kalra S, Baruah MP, Sahay R, Kishor K. Pentads and hexads in diabetes care: numbers as targets; numbers as tools. Indian J Endocrinol Metab. 2017;21(6):794.

   Not in our library10.4103/ijem.ijem_281_17

9. 9.

   Lachin JM, Genuth S, Cleary P, Davis MD, Nathan DM. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000;342(6):381-389.

   Not in our library10.1056/nejm200002103420603

10. 10.

    American Diabetes Association. Standards of medical care in diabetes—2018. Diabetes Care. 2018;41(1):S1-S155.

    Not in our library

11. 11.

    Damodaran GK, Gilsa E, Andrews M, Mathew C, George J, Ajith V. Apo lipoprotein B, total cholesterol, HDL-C, non HDL-C, LDL-C and triglycerides as risk factors of atherosclerotic vascular disease. Int J Adv Res. 2015;3(2):814-819.

    Not in our library

12. 12.

    Heine RJ, Balkau B, Ceriello A, Del Prato S, Horton ES, Taskinen MR. What does postprandial hyperglycaemia mean? Diabet Med. 2004;21(3):208-213.

    Not in our library10.1111/j.1464-5491.2004.01149.x

13. 13.

    Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28(2):103-117.

    Not in our library10.1016/0168-8227(95)01064-k

14. 14.

    ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-2572.

    Not in our library10.1056/nejmoa0802987

15. 15.

    Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010;376(9739):419-430.

    Not in our library10.1016/s0140-6736(10)60576-4

16. 16.

    Saremi A, Moritz TE, Anderson RJ, et al. Rates and determinants of coronary and abdominal aortic artery calcium progression in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care. 2010;33(12):2642-2647.

    Not in our library10.2337/dc10-1388

17. 17.

    Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American Association of Clinical Endocrinologists and American College of Endocrinology—clinical practice guidelines for developing a diabetes mellitus comprehensive care plan—2015. Endocr Pract. 2015;21(Suppl 1):1-87.

    Not in our library10.4158/ep15672.glsuppl

18. 18.

    Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129-139.

    Not in our library10.1056/nejmoa0808431

19. 19.

    Kahn CR, Weir GC, King GL, Jacobson AM, Moses AC, Smith RJ. Joslin: Diabetes Melito-14. Artmed Editora; 2009.

    Not in our library

20. 20.

    Turner R. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) (vol 352, pg 837, 1998). Lancet. 1999;354(9178):602.

    Not in our library10.1016/s0140-6736(05)77957-5

21. 21.

    Reuven Y, Dreiher J, Shvartzman P. The prevalence of diabetes, hypertension and obesity among immigrants from East Africa and the former Soviet Union: a retrospective comparative 30-year cohort study. Cardiovasc Diabetol. 2016;15:74.

    Not in our library10.1186/s12933-016-0392-7

22. 22.

    Bahendeka S, Wesonga R, Mutungi G, Muwonge J, Neema S, Guwatudde D. Prevalence and correlates of diabetes mellitus in Uganda: a population-based national survey. Trop Med Int Health. 2016;21(3):405-416.

    Not in our library10.1111/tmi.12663

23. 23.

    Gomez-Perez FJ, Aguilar-Salinas CA, Almeda-Valdes P, Cuevas-Ramos D, Garber IL, Rull JA. HbA1c for the diagnosis of diabetes mellitus in a developing country. A position article. Arch Med Res. 2010;41:302-308.

    Not in our library10.1016/j.arcmed.2010.05.007

24. 24.

    Mayige M, Kagaruki G. Tanzania STEPS Survey Report. Ministry of Health and Social Welfare and National Institute for Medial Research in Collaboration with World Health Organizaation; 2013. https://www.researchgate.net/publication/311065616_TANZANIA_STEPS_SURVEY_REPORT. Accessed Dec 23, 2017.

    Not in our library

25. 25.

    Unnikrishnan IR, Anjana R, Mohan V. Importance of controlling diabetes early–the concept of metabolic memory, legacy effect and the case for early insulinisation. J Assoc Physicians India. 2005;53:283-287.

    Not in our library

26. 26.

    World Health Organization. World Health Organization—noncommunicable diseases (NCD) country profiles, 2014. http://www.who.int/nmh/countries/bdi_en.pdf. Accessed Dec 23, 2017.

    Not in our library

27. 27.

    Kong M-F, Bickerton A. Insulin should be prescribed at the outset of diagnosis of type 2 diabetes. Pract Diab Int. 2011;28(2):85-87.

    Not in our library10.1002/pdi.1564

28. 28.

    World Health Organization. Ethiopia 2015 STEPS fast sheet. http://www.who.int/chp/steps/Ethiopia_2015_STEPS_FactSheet.pdf?ua=1. Accessed on Dec 4, 2017.

    Not in our library

29. 29.

    Manne-Goehler J, Atun R, Stokes A, et al. Diabetes diagnosis and care in sub-Saharan Africa: pooled analysis of individual data from 12 countries. Lancet Diabetes Endocrinol. 2016;4(11):903-912.

    Not in our library10.1016/s2213-8587(16)30181-4

30. 30.

    Atun R, Davies JI, Gale EAM, et al. Diabetes in sub-Saharan Africa: from clinical care to health policy. Lancet Diabetes Endocrinol. 2017;5(8):622-667.

    Not in our library10.1016/s2213-8587(17)30181-x

31. 31.
    Readiness of Ugandan health services for the management of outpatients with chronic diseases · 2015

    No notice
32. 32.

    Vedanthan R, Kamano JH, Bloomfield GS, Manji I, Pastakia S, Kimaiyo SN. Engaging the entire care cascade in Western Kenya: a model to achieve the cardiovascular disease secondary prevention roadmap goals. Glob Heart. 2015;10(4):313-317.

    Not in our library10.1016/j.gheart.2015.09.003

33. 33.

    Nnko S, Bukenya D, Kavishe BB, et al. Chronic diseases in North-West Tanzania and Southern Uganda. Public perceptions of terminologies, aetiologies, symptoms and preferred management. PLoS One. 2015;10(11):e0142194.

    Not in our library10.1371/journal.pone.0142194

34. 34.

    Nielsen J, Bahendeka SK, Bygbjerg IC, Meyrowitsch DW, Whyte SR. Accessing diabetes care in rural Uganda: economic and social resources. Glob Public Health. 2017;12(7):892–908.

    Not in our library10.1080/17441692.2016.1172100

35. 35.

    Cook AR. Notes on the disease met with in Uganda, Central Africa. J Trop Med. 1901;4(17):5-8.

    Not in our library

36. 36.

    Amendezo E, Walker Timothy D, Karamuka V, et al. Effects of a lifestyle education program on glycemic control among patients with diabetes at Kigali University Hospital, Rwanda: a randomized controlled trial. Diabetes Res Clin Pract. 2017;126:129-137.

    Not in our library10.1016/j.diabres.2017.02.001

37. 37.

    Marshall SL, Edidin D, Arena VC, et al. Prevalence and incidence of clinically recognized cases of type 1 diabetes in children and adolescents in Rwanda, Africa. Diabet Med. 2015;32(9):1186-1192.

    Not in our library10.1111/dme.12701

38. 38.

    Ngwiri T, Were F, Predieri B, Ngugi P, Iughetti L. Glycemic control in Kenyan children and adolescents with type 1 diabetes mellitus. Int J Endocrinol. 2015;2015:761759.

    Not in our library10.1155/2015/761759

39. 39.

    Majaliwa ES, Munubhi E, Ramaiya K, et al. Survey on acute and chronic complications in children and adolescents with type 1 diabetes at Muhimbili National Hospital in Dar es Salaam, Tanzania. Diabetes Care. 2007;30(9):2187-2192.

    Not in our library10.2337/dc07-0594

40. 40.

    Osujih M. Exploration of the frontiers of tradomedical practices: basis for development of alternative medical healthcare services in developing countries. J R Soc Health. 1993;113(4):190-194.

    Not in our library10.1177/146642409311300409

Cited by papers we hold 3

• Enhancing Choices Regarding the Administration of Insulin Among Patients With Diabetes Requiring Insulin Across Countries and Implications for Future Care · 2022
  Not checked
• Gut microbiota: A new target for T2DM prevention and treatment · 2022
  No notice
• Continuous glucose monitoring assessment of metabolic control in east African children and young adults with type 1 diabetes: A pilot and feasibility study · 2020
  Not checked

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.